GSK, Novartis agree to $4.5M penalty for misleading Osteo Gel claims

Bird & Bird 2020-05-04 3:40 pm By Alison Eveleigh | Sydney

Please login to bookmark

GlaxoSmithKline and Novartis have agreed to a combined penalty of $4.5 million after the Australian Competition and Consumer Commission accused the pharmaceutical giants of making misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au